## 促进健康可及

我们始终坚守守护大众健康的初心，让大众能够以经济实惠的价格，便捷获取安全可靠的健康产品与专业服务，切实履行健康责任与社会承诺，让健康福祉惠及更多群体。

### 公平合理定价

我们严格遵循相关法律法规要求，保护市场公平竞争，确保患者能够以合理公平的价格获得药品。在不同国家市场根据当地的经济水平、患者实际需求和支付能力，制定公平灵活的定价机制。我们持续推动产品纳入医保目录与集采，依据国家规定进行分级定价，患者使用不同类别药品可享受不同比例医保报销，以实际行动落实药品公平透明定价要求。

### 发展中国家与新兴市场发展

昆药集团计划到 2027 年在多个核心新兴市场实现主力产品准入与规模化销售，包括吉尔吉斯斯坦、乌兹别克斯坦、津巴布韦、尼日利亚等发展中国家，持续探索国际业务合作渠道与模式，推动产品上市批准与销售，加大在新兴市场的布局与份额，为全球患者提供更优质、更可及的医药解决方案。同时，积极践行国际社会责任，在乌兹别克、埃塞俄比亚和老挝等国家，对当地医疗工作者等对象开展涵盖多个专业领域的援外培训，重点推动中医药文化与医疗技术向“一带一路”国家及萨尔瓦多国家传播，赋能当地医疗人才培养与卫生能力建设，搭建文明互鉴与技术交流的桥梁，践行构建人类卫生健康共同体的责任担当。

药物警戒方面，昆药集团设立了药物安全委员会，负责重大或紧急药品安全事件处置、风险控制决策以及其他与药物警戒有关的重大事项。为规范药品全生命周期的药物警戒活动，确保药品不良反应及其他与用药有关的有害反应能够得到有效的监测、识别、评估和控制，昆药集团严格遵守《药品不良反应报告和监测管理办法》《药物警戒质量管理规范》等法规指南。同时，我们通过国际组织或第三方渠道进入到印度尼西亚，越南，乌兹别克斯坦等国家推进药品的药物警戒建设工作，包括但不限于药品不良反应(Adverse Drug Reaction,ADR)的监测、

报告、分析、评价及反馈等工作，制定药物警戒计划，覆盖对象包括医生、护士、药师、辅助医疗专业人员及相关专业协会，包括建立和维护药品不良反应监测体系，确保药品不良反应的及时发现、准确报告和有效处理。

公司于 2025 年成功通过世界卫生组织（WHO）的 GMP 检查，相关原料药获得 WHOPQ 认证，为参与全球药品采购与市场拓展奠定了关键基础。依托自身 WHO PQ、GMP 全流程质控经验，通过研修班等输出国际药品生产规范，向非洲本土药企传授车间管控、检验标准实操方案，指导当地制造商完善质量体系、对标 WHO GMP 国际生产准则，持续提升中低收入国家本土制药规范化水平。

此外，天士力集团亦积极响应“一带一路”倡议，与发展中国家或新兴市场在药品研发、注册等方面加强交流、共享共建，将优质中药产品与健康服务输送至沿线国家，以中医药为桥梁实现全球民生健康普惠，让中医药为“一带一路”沿线民众的健康福祉贡献力量。

# Improving Access to Healthcare

We remain committed to our original aspiration of safeguarding public health. We ensure that safe and reliable health products and professional services are accessible to the public at affordable prices. By earnestly fulfilling our health responsibilities and social commitments, we expand health benefits to broader populations.

## Fair and Reasonable Pricing

We strictly adhere to relevant laws and regulations to protect fair market competition and ensure patients can obtain medicines at reasonable and fair prices. In different national markets, we establish fair and flexible pricing mechanisms based on local economic conditions and the actual needs and payment capabilities of patients. We continuously promote the inclusion of our products in the national medical insurance catalog to benefit public welfare with more favorable drug prices, and implement tiered pricing in accordance with national requirements. Patients are entitled to medical insurance reimbursement at different rates for various categories of medicines. We deliver fair and transparent pharmaceutical pricing through concrete practices.

## Expansion in Developing Countries and Emerging Markets

By 2027, Kun Pharmaceutical Group plans to secure market access and achieve scaled-up sales of its core products in several key emerging markets, including developing countries such as Kyrgyzstan, Uzbekistan, Zimbabwe and Nigeria. We continuously explore channels

and models for international business cooperation to advance product registration and commercialization, expand our footprint and market share in emerging markets, and deliver higher-quality, more accessible pharmaceutical solutions for patients worldwide.
Meanwhile, we actively fulfil international social-responsibility obligations. We conduct foreign-aid training covering multiple professional fields targeting local medical workers and other participants in Uzbekistan, Ethiopia, Laos and other low- and middle-income countries. We focus on disseminating Traditional Chinese Medicine culture and medical technologies to Belt and Road partner countries as well as El Salvador. We boost the development of local medical talents and health-system capacity-building, build bridges for cultural mutual learning and technical exchange, and honor our commitment to building a global community of public health.
In terms of pharmacovigilance, Kun Pharmaceutical Group has established a Drug Safety Committee to handle major or emergency drug-safety incidents, make risk-control decisions and address other material pharmacovigilance-related matters. To standardize pharmacovigilance practices across the full-life-cycle of medicines and ensure effective monitoring, identification, assessment and control of adverse drug reactions and other harmful medication-related reactions, Kun Pharmaceutical Group strictly complies with the Measures for the Administration of Adverse Drug Reaction Reporting and Monitoring, the Good Pharmacovigilance Practices. Furthermore, through international organizations and third-party partnerships, we advance pharmacovigilance capacity-building in Indonesia, Vietnam, Uzbekistan and other low- and middle-income countries. Our work includes but is not limited to the monitoring, reporting, analysis, evaluation and feedback of

Adverse Drug Reactions (ADR). We formulate pharmacovigilance plans targeting physicians, nurses, pharmacists, allied-health professionals and relevant professional associations. We establish and maintain adverse-drug-reaction surveillance systems to ensure timely detection, accurate reporting and effective handling of adverse drug reactions.

In 2025, the Company successfully passed the World Health Organization (WHO) GMP inspection, and relevant active pharmaceutical ingredients obtained WHO PQ certification. This lays a critical foundation for participating in global pharmaceutical procurement and international market expansion. Leveraging our in-house WHO-PQ and GMP end-to-end quality-control expertise, we share international pharmaceutical manufacturing standards via training programmes. We transfer practical solutions for workshop management and testing standards to local African pharmaceutical manufacturers, guide local producers to improve quality systems and align with WHO GMP international manufacturing requirements, and continuously raise the standardization level of local pharmaceutical production in low- and middle-income countries.

In addition, Tasly Group actively responds to the Belt-and-Road Initiative. It strengthens exchanges and joint development with developing-country and emerging-market partners in pharmaceutical R&D and registration. It delivers high-quality TCM products and health services to countries along the Belt-and-Road routes. Taking Traditional Chinese Medicine as a bridge, it advances inclusive global public-health outcomes and enables TCM to contribute to the well-being of populations in Belt-and-Road-related countries.